Given the revolutionary impact of the combination of BRAF and MEK inhibitors in the clinical management of melanoma, it was also evaluated in BRAF-mutated mCRC by Corcoran et al. In total, 43 patients were treated with dabrafenib and trametinib, with 56% of stable disease and an ORR of 12% [76]. This evidence concerns the gene BRAF and melanoma.